If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
Dyadic International, Inc. (DYAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.The profile contains critical company information including:- Business description – A detailed description of the company's operations and business divisions.- Corporate strategy – Analyst's summarization of the company's business strategy.- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.- Company history – Progression of key events associated with the company.- Major products and services – A list of major products, services and brands of the company.- Key competitors – A list of key competitors to the company.- Key employees – A list of the key executives of the company.- Executive biographies – A brief summary of the executives’ employment history.- Key operational heads – A list of personnel heading key departments/functions.- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.HighlightsDyadic International, Inc. (Dyadic) is a biotechnology company. It discovers, develops, manufactures and commercializes enzymes and other proteins for the bioenergy, biopharmaceutical, biochemical and industrial enzyme industries. The company manufactures and sells liquid and dry enzyme products to global customers for use within the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and biofuel industries. Dyadic uses its patented and proprietary technologies, namely, Trichoderma and C1 fungal strains, to conduct research and produce its industrial enzymes. The company operates along with its laboratories and subsidiaries in the US and the Netherlands. Dyadic is headquartered in Jupiter, Florida, the US.Dyadic International, Inc. Key Recent DevelopmentsApr 28, 2015: Dyadic International Receives Two Additional Research Milestone Payments From BASFMar 18, 2015: Dyadic International Announces The Appointment Of Jack Kaye To Its Board of DirectorsMar 11, 2015: Dyadic International Reports 2014 Year End Financial ResultsJan 12, 2015: Dyadic Appoints Michael Tarnok As Chairman Of The Board Of DirectorsNov 21, 2013: Dyadic International To Present At Two Major Conferences In December 2013Key benefits of buying this profile include:You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.Gain key insights into the company for academic or business research.- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.Note: Some sections may be missing if data is unavailable for the company
Table of ContentsTable of Contents 2List of Tables 4List of Figures 5Section 1 - About the Company 6Dyadic International, Inc. - Key Facts 6Dyadic International, Inc. - Key Employees 7Dyadic International, Inc. - Key Employee Biographies 8Dyadic International, Inc. - Major Products and Services 9Dyadic International, Inc. - History 10Dyadic International, Inc. - Company Statement 13Dyadic International, Inc. - Locations And Subsidiaries 14Head Office 14Other Locations & Subsidiaries 14Section 2 – Company Analysis 15Dyadic International, Inc. - Business Description 15Dyadic International, Inc. - Corporate Strategy 17Dyadic International, Inc. - SWOT Analysis 18SWOT Analysis - Overview 18Dyadic International, Inc. - Strengths 18Strength - C1 Platform Technology 18Strength - Research and Development 18Strength - Partnerships and Collaborations 18Dyadic International, Inc. - Weaknesses 19Weakness - Declining Operational Performance 19Dyadic International, Inc. - Opportunities 20Opportunity - Growing Demand for Ethanol: Brazil 20Opportunity - Growing Demand for Industrial Enzymes 20Opportunity - Growth Opportunities in Emerging Markets 20Dyadic International, Inc. - Threats 21Threat - Concentration of Customers 21Threat - Intense Competition 21Threat - Environmental Regulations 21Dyadic International, Inc. - Key Competitors 22Section 3 – Company Financial Ratios 23Financial Ratios - Capital Market Ratios 23Financial Ratios - Annual Ratios 24Performance Chart 26Financial Performance 26Financial Ratios - Interim Ratios 27Financial Ratios - Ratio Charts 28Section 4 – Company's Lifesciences Financial Deals and Alliances 29Dyadic International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 29Dyadic International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 30Dyadic International, Inc., Recent Deals Summary 31Section 5 – Company's Recent Developments 32Apr 28, 2015: Dyadic International Receives Two Additional Research Milestone Payments From BASF 32Mar 18, 2015: Dyadic International Announces The Appointment Of Jack Kaye To Its Board of Directors 33Mar 11, 2015: Dyadic International Reports 2014 Year End Financial Results 34Jan 12, 2015: Dyadic Appoints Michael Tarnok As Chairman Of The Board Of Directors 36Nov 12, 2014: New U.S. Patent Issued To Dyadic International 37Aug 14, 2014: Dyadic International Reports Q2 2014 Financial Results 38Jul 30, 2014: Thomas Dubinski joins Dyadic as Chief Financial Officer 40Jun 12, 2014: Dyadic Appoints Michael Tarnok, Chairman Of Keryx And Former Pfizer Senior Vice President, To Board Of Directors 41May 08, 2014: Dyadic International Reports Q1 2014 Financial Results 42May 06, 2014: Dyadic International Strengthens European Leadership Team 45Section 6 – Appendix 46Methodology 46Ratio Definitions 46About GlobalData 50Contact Us 50Disclaimer 50List of TablesDyadic International, Inc., Key Facts 6Dyadic International, Inc., Key Employees 7Dyadic International, Inc., Key Employee Biographies 8Dyadic International, Inc., Major Products and Services 9Dyadic International, Inc., History 10Dyadic International, Inc., Other Locations 14Dyadic International, Inc., Subsidiaries 14Dyadic International, Inc., Key Competitors 22Dyadic International, Inc., Ratios based on current share price 23Dyadic International, Inc., Annual Ratios 24Dyadic International, Inc., Interim Ratios 27Dyadic International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 29Dyadic International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 30Dyadic International, Inc., Recent Deals Summary 31Currency Codes 46Capital Market Ratios 46Equity Ratios 47Profitability Ratios 47Cost Ratios 48Liquidity Ratios 48Leverage Ratios 49Efficiency Ratios 49List of FiguresDyadic International, Inc., Performance Chart (2010 - 2014) 26Dyadic International, Inc., Ratio Charts 28Dyadic International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 29Dyadic International, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 30